MedQuist Announces Entry of Final Judgment Approving Settlement and Dismissing Medical Transcriptionist Cl... ( MOUNT LAUREL N.J. April 2 /- MedQuist...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

MedQuist Announces Entry of Final Judgment Approving Settlement and Dismissing Medical Transcriptionist Class Action

Date:4/2/2009

MOUNT LAUREL, N.J., April 2 /PRNewswire-FirstCall/ -- MedQuist Inc. (Nasdaq: MEDQ), a leading provider of medical transcription services, is pleased to announce entry of final judgment approving settlement and dismissing the consolidated medical transcriptionist class action commenced against the Company following disclosure of the results of the internal review of its historic billing practices in July 2004. MedQuist cares deeply about its workforce, and throughout this litigation the Company maintained that it has always correctly paid its medical transcriptionists, that it did nothing wrong, and that the allegations in the suit were completely meritless. The Court's action this week vindicates the Company's position: "[N]otwithstanding Plaintiffs' expansive discovery and investigative work, no evidence emerged to support their allegations that MedQuist had systematically underpaid its transcriptionists." The full text of the Court's Final Judgment and Opinion are available through the Company's Web site at www.MedQuist.com.

As originally reported by MedQuist in December 2004 and October 2005, certain individual medical transcriptionists commenced class action litigation against the Company alleging that MedQuist systematically and wrongfully underpaid medical transcriptionists. After it became clear that Plaintiffs could not prove the claims alleged against MedQuist, the parties reached a settlement, whereby MedQuist agreed to an injunction requiring it to implement certain measures to ensure transparency in medical transcription pay. MedQuist hopes that as a recognized leader in the medical transcription field, its agreement to increase transparency will pave the way for similar measures throughout the industry.

As part of the settlement, the Company also agreed to pa
'/>"/>

SOURCE MedQuist Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine news :

1. MedQuist Announces Resolution of SEC Investigation
2. MedQuist Reports Fourth Quarter and Year End 2008 Results
3. MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits
4. New Jersey-Based MedQuist Pays U.S. $6.6 Million to Resolve False Claims Act Allegations
5. MedQuist and Primordial to Demonstrate Integrated Applications at RSNA
6. MedQuist and Clario Form Partnership to Integrate zVision Radiology Practice Management Software with SpeechQ for Radiology
7. MedQuist Introduces SpeechQ for Radiology Integrated with RadWorkFlow
8. MedQuist Reports Third Quarter 2008 Results
9. MedQuist Reports Second Quarter 2008 Results
10. MedQuist Announces Changes to Board of Directors
11. MedQuist Announces Declaration of $2.75 per share Dividend on Common Stock

Post Your Comments:

Breaking Medicine News(10 mins):Health News:Genetic variations indicate risk of recurrence, secondary cancer among head and neck cancer patients 2 Health News:Hospice Foundation of America Presents Webinar on 'Bereavement Camps for Kids: Benefits and Challenges' 2 Health News:Kaiser Permanente CIO Philip Fasano Named One of Computerworld's Top 100 IT Leaders for 2010 2 Health News:Lung Cancer Alliance-Georgia Hails Senate Leadership on Lung Cancer Mortality Reduction Act of 2009 2 Health News:Lung Cancer Alliance-Georgia Hails Senate Leadership on Lung Cancer Mortality Reduction Act of 2009 3 Health News:Second-line CML drugs evoke faster response than front-line therapy 2

[1] Genetic variations indicate risk of recurrence, secondary cancer among head and neck cancer patients [0] Hospice Foundation of America Presents Webinar on 'Bereavement Camps for Kids: Benefits and Challenges'[0] Kaiser Permanente CIO Philip Fasano Named One of Computerworld's Top 100 IT Leaders for 2010 [0] Lung Cancer Alliance-Georgia Hails Senate Leadership on Lung Cancer Mortality Reduction Act of 2009 [0] Second-line CML drugs evoke faster response than front-line therapy

ADA Urges President Bush Not to Veto Critical Appropriations Bill AUA releases new guidelines on non-muscle invasive bladder cancer Warning for women who binge drink Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 New Study: Health Insurance Mandates on Employers Hurt Low-Income Employees Physics provides new insights on cataract formation

Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7 Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2 Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3 Van Andel Institute Cuts Ribbon on $178 Million Expansion 2 Van Andel Institute Cuts Ribbon on $178 Million Expansion 3 Van Andel Institute Cuts Ribbon on $178 Million Expansion 4 Call to the Youth of America 3A Palms for Life Fund Launches Film Competition to Document Hunger in the United States 53180 1 Call to the Youth of America 3A Palms for Life Fund Launches Film Competition to Document Hunger in the United States 53180 2 All Nursing Schools Sheds Light on Online Nursing Degree Opportunities in a Rough Economy 53176 1 All Nursing Schools Sheds Light on Online Nursing Degree Opportunities in a Rough Economy 53176 2 Higher drug doses needed to defeat tuberculosis UT Southwestern researchers report 53172 1 Higher drug doses needed to defeat tuberculosis UT Southwestern researchers report 53172 2 Higher drug doses needed to defeat tuberculosis UT Southwestern researchers report 53172 3

[0] Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology [0] Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program [0] Van Andel Institute Cuts Ribbon on $178 Million Expansion

Other Medicine Technology:Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 2 Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 3 Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 4 Isotechnika's Lead Drug, ISA247, To Be Highlighted at the,Association for Research in Vision and Ophthalmology (ARVO) Annual,Meeting 2 Isotechnika's Lead Drug, ISA247, To Be Highlighted at the,Association for Research in Vision and Ophthalmology (ARVO) Annual,Meeting 3 Isotechnika's Lead Drug, ISA247, To Be Highlighted at the,Association for Research in Vision and Ophthalmology (ARVO) Annual,Meeting 4

Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 Isotechnika's Lead Drug, ISA247, To Be Highlighted at the,Association for Research in Vision and Ophthalmology (ARVO) Annual,Meeting

Medicine Products:

Allsport Ankle Ortho II QualCare™ Compression Ankle Support VenaFlow® System SCD EXPRESS Compression System

MedQuist Announces Entry of Final Judgment Approving Settlement and Dismissing Medical Transcriptionist Cl...( MOUNT LAUREL N.J. April 2 /- MedQuist...),Health